Medical device company TransEnterix Inc (NYSE MKT:TRXC) stated on Monday that it recorded a net loss of USD120.0m (USD1.07 per share) for the full year ended 31 December 2016.
This reflects a decrease in earnings when compared with net loss of USD46.9m (USD0.59 per share) for the full year ended 31 December 2015.
Revenues of USD1.5m were generated for the full year ended 31 December 2016, over nil for the full year ended 31 December 2015.
The company said the 2016 revenues represent the sale of a Senhance system, net of deferred revenue, as well as the recognition of deferred and service revenue associated with existing placements.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development